Radiation Oncology
This case presentation illustrates many relevant aspects of the multimodality approach toward the treatment of breast cancer. This 55-year-old female presented originally in the premenopausal setting, with a T2 (2.5 cm) N1 (1/17 lymph nodes involved) well-differentiated intraductal and infiltrating ductal carcinoma of the left breast. Consideration is given to both the local-regional aspects of therapy and the systemic component of treatment when evaluating a given patient with breast cancer. The local regional management of breast cancer has evolved from primary surgical management with modified radical mastectomy to that of breast conservation in appropriate patients, consisting of lumpectomy, followed by adjuvant radiation therapy directed to the affected breast, and tumor bed. Multiple randomized studies have proven the equivalence of the breast conservation approach to that of more radical surgery, demonstrating no significant difference in local-regional recurrence, distant metastasis, or long-term survival. [1] [2] [3] [4] [5] [6] The goals of the breast conservation approach are to eradicate microscopic foci of multicentric cancer with moderate doses of radiation, to minimize risk of local recurrence at the primary site, to maximize benefits of quality of life with minimal risk of complications, and to attain an acceptable cosmetic result.
To attain optimal results with breast conservation, patients must be appropriately selected, identifying factors that impact tumor control, cosmetic outcome, and potential complications. Factors associated with a high risk for local recurrence in the setting of breast conser vation include the presence of gross multicentric disease or diffuse microcalcifications within the breast, 7-9 as well as extensive intraductal component (EIC) with positive margins of resection. 10, 11 Extensive intraductal component is defined as the presence of an intraductal carcinoma comprising 25% or more of the primary invasive tumor and the presence of intraductal carcinoma in the surrounding normal breast tissue. 12 The increased risk for breast recurrence in EIC-positive tumors is related to the presence of significant residual tumor burden following gross excision. An elegant study examined the pathologic findings of mastectomy specimens with mammographic correlation and noted that EICpositive tumors were significantly more likely to have residual tumor at greater distance from the primary than EIC-negative tumors. 13 Young age, ≤ 35 years, has also been identified as a clinical factor associated with an increased risk of breast cancer recurrence, 11, 14, 15 however, without any significant difference in outcome when treated with mastectomy as compared with breast conservation. 16, 17 Cosmetic considerations include location of the primary tumor, with less optimal outcome in patients with a subareolar location, as well as size of primary tumor as it relates to the size of the breast. The risks of complications from treatment with radiation therapy increase in patients with a preexistent history of collagen vascular disease including scleroderma and lupus. 18 These patients have been noted to develop marked fibrosis and possible soft tissue necrosis following conventional doses of radiation. 19 Similarly, patients who have received mantle irradiation for Hodgkin's disease and subsequently developed breast cancer may experience complications with reirradiation of the breast area. Last, use of radiation therapy in the breast conservation approach is contraindicated in women who are pregnant, due to potential harmful effects on the developing fetus.
Details within this patient's history that would be helpful in determining the appropriateness of breast conser vation up front include the exact mammographic findings, including the description of the calcifications: microcalcifications versus macrocalcifications, clustered versus diffuse, present in single versus multiple quadrants of the breast. More commonly associated with malignancy are findings of clustered microcalcifications within a particular quadrant of the breast. If noted to be present in more than one quadrant, concern may arise as to multifocality, which is relevant in this patient, as she subsequently developed recurrent disease within the left breast, unknown whether related to her presenting malignancy or to a second breast cancer. Assuming mammographic findings suggested a single focus of disease within the breast; pathologic findings of margin status as negative, close (< 2 mm), or positive; and the presence or absence of extensive intraductal component (EIC) are relevant features in the decision to proceed with breast conservation. Although the presence of positive margins or EIC is not an absolute contraindication to breast conservation, such features are associated with a higher risk for local recurrence. 10, 20, 21 The target of radiation therapy in the setting of breast conservation is typically the entire affected breast, and possibly regional lymph nodes. The concept of treatment directed to less than the entire breast for early invasive cancer has been evaluated by prospective randomized trials, indicating risk of breast recurrence ranging between 10% and 43% without the addition of radiation to the breast following lumpectomy, as compared with a 3% to 13% risk when adjuvant radiation therapy is delivered following lumpectomy. 22, 23 It appears that even in highly selected patients with tumors < 1 cm in size with negative axillary lymph nodes, and negative margins of resection treated with adjuvant tamoxifen hormonal therapy, that radiation therapy is clearly of benefit in reducing the risk of local recurrence. 24 The typical prescribed dose is 4500-5000 cGy in 25-28 fractions followed by a boost to the primary tumor bed for an additional 1000-1400 cGy in 5-7 fractions, bringing the total prescribed dose to the tumor bed to 60 Gy. The role of the tumor bed boost has recently been defined more clearly by a recently published randomized study comparing the outcomes of patients randomized to boost versus no boost following treatment with radiation to the whole breast, indicating clear improvement in local control in patients younger than 50 years of age when treated with a boost to the primary tumor bed. 25 Radiation therapy delivered to regional lymph nodes is reserved for patients presenting with 4 or more involved axillary lymph nodes, or with primary tumors measuring greater than 5 cm in size, and is most commonly delivered to the supraclavicular fossa. The risk of axillary nodal recurrence is quite low in the setting of an appropriate lymph node dissection with removal of ≥ 10 axillary nodes, and therefore radiation to the axilla in the adjuvant setting is less commonly employed.
The effects of radiation therapy are primarily local and relate to that part of the body toward which it is directed. Three-dimensional treatment-planning techniques are more commonly utilized to ensure appropriate homogeneous coverage of the breast, with minimization of dose to surrounding normal anatomic structures, including lung and heart. The adverse effects of radiation therapy are divided into acute effects, those that commonly manifest during treatment, and late effects, which can occur weeks to months following completion of therapy. Common acute effects of radiation therapy delivered to the breast include erythema of the skin of the affected breast, hyperpigmentation of the skin, dry desquamation, possible moist desquamation-more common in women with large breasts-edema of the breast with mild tenderness, fatigue, and possible bone marrow depression, the latter related to volume of marrow in the field, as well as pretreatment with chemotherapy. Acute effects resolve within 4 to 6 weeks of completion of radiation therapy; however, mild edema of the breast, as well as hyperpigmentation of skin, may persist for a longer duration. Late effects of radiation therapy are attributed to parenchymal cellular hypoplasia of stem cells and alterations in the fine vasculature and fibroconnective tissues. Late effects of radiation therapy to the breast include a risk of pneumonitis and pericarditis in < 2% of treated patients, lymphedema in the ipsilateral upper extremity, rib fracture, and a small risk of secondary malignancies. 26 It remains unclear the role of complementary use of vitamins and specifically antioxidants in an effort toward reduction in severity of effects of radiation therapy, which I hope will be addressed further in this discussion. Both acute and late effects of treatment with radiation therapy can be increased by the use of concurrent chemotherapy, and therefore treatment with both modalities is often sequenced.
The order of sequence of radiation therapy and chemotherapy in the adjuvant setting has been a matter of controversy. As the goals of each modality are different, it has been difficult historically to understand how best to incorporate both treatments. It is understood that delay in initiation of radiation therapy following lumpectomy can be associated with a higher rate of local recurrence. 27, 28 Similarly, there is concern that in those patients who harbor micrometastatic systemic disease, that delay in chemotherapy delivery will lead to higher rates of distant metastasis. A randomized study has been reported, examining outcome in patients randomized to 12 weeks of adjuvant chemotherapy delivered either before or after radiation therapy. Noted was an increase in distant or regional recurrence in the radiation-first arm, and an increase in local recurrence in the chemotherapy-first arm. Concluded was that in patients at substantial risk for systemic metastasis, it is preferable to deliver systemic chemotherapy first, followed by radiation therapy. 29 In this patient, a sandwich technique was utilized, also an accepted method of integrating the 2 modalities, with the theoretical benefits of administering both treatments in a timely manner.
Beyond the initial diagnosis and course of therapy, this patient's history is quite interesting, with the development of a cluster of microcalcifications within the left breast 7 years later. Relevant to the determination of whether the subsequent diagnosis of invasive ductal carcinoma represents a true recurrence of the original breast cancer versus a new primary is the location of the microcalcifications relative to the location of the original primary malignancy. Local recurrences are characterized by tumors of same histologic subtype, located within the same quadrant, or within 3 cm from the primary tumor bed. If found to be of different histologic subtype, or in a different location within the breast, such findings are consistent with a new primary. 30, 31 It is difficult to make a meaningful conclusion in this patient as to whether the current presentation indicates recurrent or new disease, as the histology is similar in both presentations and the location of the more recently diagnosed carcinoma is not identified in the history.
Studies suggest that patients presenting with a new primary tumor have improved prognosis relative to those with local recurrences. Findings indicate a longer mean time to breast relapse in patients with new primaries (7.3 years vs 3.7 years), as well as improved overall survival, disease-free survival, and cause-specific survival. 30, 31 Also reported is an improved prognosis in those patients who present with "late" local recurrences, defined as greater than 5 years from presenting diagnosis, as compared with recurrences occurring less than 5 years from diagnosis (89% vs 65% 5year survival). 32, 33 Therefore, either scenario in this patient's presentation suggests a favorable long-term prognosis due to the long interval between diagnosis and the current presentation, as well as the possibility of a new primary malignancy. Local-regional treatment for breast recurrence or new primary following prior breast conservation is a modified radical mastectomy, which was appropriately performed in this patient. There is limited data examining the role of a more conservative surgical approach in the treatment of local recurrence following breast conservation, confirming a high incidence of subsequent local failures. Mastectomy specimens frequently reveal substantial residual disease outside the cavity, with 29% of evaluated specimens demonstrating residual tumor in 2 or more quadrants of the breast in one series. 34 The role of prophylactic mastectomy of the contralateral breast in the absence of BRCA1 and BRCA2 mutations and a strong family history is unclear, however, and is a personal decision. For patients known to have BRCA1 and BRCA2 mutations, prophylactic mastectomy has been shown to reduce the incidence of development of subsequent breast cancer. 35 The role of sentinel lymph node biopsy in the setting of prophylactic mastectomy similarly is unclear. In one study, over a 67-month period, 57 patients underwent prophylactic mastectomy with sentinel lymph node biopsy after 4 quadrant periareolar injections of radiocolloid and blue dye. 36 Findings included 2 patients who were found to have a positive sentinel lymph node by immunohis-tochemistry only, without occult disease within the breast, as well as 2 patients found to have invasive breast cancer within the mastectomy specimen, however, with negative lymph nodes. The rationale relates to the inability to perform sentinel node biopsy following prophylactic mastectomy, in the event that invasive disease was found.
The finding in this patient of a positive sentinel node in the absence of malignancy within the right breast is interesting, especially as it exhibits similar histologic features to the left breast carcinoma. Nevertheless, due to separate anatomic lymphatic drainage between the 2 breasts, I believe the right breast sentinel node is unrelated to the left breast cancer, and likely is a result of an occult primary in the right breast. One might have considered a subsequent axillary lymph node dissection; however, as estrogen receptors were expressed, an appropriate systemic therapy is understood, without significant additional information to be derived. Finally, although recent studies have indicated survival benefit with the use of adjuvant chest wall and regional nodal irradiation in nodepositive patients, such therapy has been reserved for patients with 4 or more involved nodes, until further studies confirm the benefit in patients with 1 to 3 involved lymph nodes.
Beyond Arimidex hormonal therapy, I believe most other worthwhile interventions will be directed toward a healthy lifestyle, one that limits stress, incorporating a healthy diet with diminished fat intake and exercise. I look forward to learning additional complementary approaches toward the continued health of this patient.
